Bronchiectasis Drugs Market with COVID-19 Impact Analysis, By Drug Class (Antibiotics, Mucolytics, Bronchodilators, Anti-inflammatory agents), By Route of Administration (Oral, Inhalation, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Bronchiectasis Drugs Market size was valued at USD 481.71 Million in 2022, expanding at a CAGR of 5.1 % from 2023 to 2030.
Bronchiectasis pharmaceuticals are medications used to treat the symptoms and problems of bronchiectasis, a chronic lung disorder characterized by bronchial tube enlargement and inflammation. These medications are intended to treat symptoms such as persistent cough, excessive mucus production, and recurring lung infections. Antibiotics are often administered drugs to treat or prevent infections, bronchodilators to expand airways, and mucolytics to thin and promote mucus removal. Treatment strategies are customized to specific patient requirements, with an emphasis on symptom management, infection avoidance, and increasing total lung function to improve bronchiectasis patients\' quality of life.
Bronchiectasis Drugs Market- Market Dynamics
- Rising awareness of this often-underdiagnosed condition propel market demand
More instances of bronchiectasis are being detected as medical understanding and diagnostic technologies improve. Furthermore, an ageing population and a rise in chronic respiratory disorders raise the need for effective therapies. Because of the increased awareness and patient population, pharmaceutical firms and researchers are investing in the development of improved bronchiectasis care options, including innovative drugs. A important impetus is the desire to enhance the quality of life for bronchiectasis patients and minimize the burden of recurring infections and symptoms.
Bronchiectasis Drugs Market- Key Insights
- As per the analysis shared by our research analyst, the global Bronchiectasis Drugs market is estimated to grow annually at a CAGR of around 5.1% over the forecast period (2023-2030)
- The Bronchiectasis Drugs industry is projected to grow at a significant rate due to rising awareness of this often-underdiagnosed condition.
- Based on Drug Class segmentation, Antibiotics was predicted to show maximum market share in the year 2022
- Based on Route of Administration segmentation, Oral was the leading Drug Class in 2022
- On the basis of region, North America was the leading revenue generator in 2022
Bronchiectasis Drugs Market- Segmentation Analysis:
The Global Bronchiectasis Drugs Market is segmented on the basis of Drug Class, Route of Administration, Distribution Channel, and Region.
The market is divided into four categories based on Drug Class: Antibiotics, Mucolytics, Bronchodilators, and Anti-inflammatory agents. The Antibiotics dominates the market. Antibiotics are vital in the therapy of bronchiectasis because they help control and prevent recurring lung infections, a frequent consequence of the illness. Antibiotics target and destroy the germs that cause these illnesses, improving patient symptoms, lung function, and general quality of life.
The market is divided into three categories based on Route of Administration: Oral, Inhalation, Intravenous. The Oral sector dominates the market and is likely to maintain its dominance during the forecast period. Oral bronchiectasis medications are in high demand because they offer patients with easy and effective therapy alternatives. These treatments, which are often antibiotics and bronchodilators, may be taken orally, making them easier to administer and increase patient adherence, particularly for those with chronic respiratory disorders like bronchiectasis.
Bronchiectasis Drugs Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Several reasons have contributed to an increase in the demand for bronchiectasis medications in North America. The region\'s aging population is more vulnerable to chronic respiratory disorders such as bronchiectasis. Second, more accurate diagnoses have resulted from enhanced diagnostic skills and knowledge among healthcare practitioners. Third, environmental variables such as air pollution and exposure to respiratory irritants contribute to bronchiectasis prevalence. Finally, patient advocacy organizations and healthcare campaigns emphasize the need for proper bronchiectasis treatment. As a result, pharmaceutical businesses and healthcare professionals in North America are seeing an increase in demand for pharmaceuticals that relieve symptoms, prevent infections, and improve patients\' quality of life.
Bronchiectasis Drugs Market- Competitive Landscape:
The bronchiectasis medicine market is characterized by a small number of specialised therapies licensed for the ailment. Some of the key treatment alternatives are provided by leading pharmaceutical firms. However, this field lacks a diverse set of specialized medications, and therapy is mostly comprised of repurposed antibiotics, bronchodilators, and mucolytics. This constraint has offered an opportunity for new medication development as businesses investigate novel therapeutics targeted at targeting the underlying causes and improving outcomes for those suffering from bronchiectasis, offering opportunities for growth and improvement in the sector.
Recent Developments:
- In May 2023, Insmed Incorporated, a worldwide biopharmaceutical company with a mission to improve the lives of patients suffering from severe and uncommon illnesses, announced today that adult patient enrolment in its key ASPEN trial of brensocatib is now complete..
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BRONCHIECTASIS DRUGS MARKET KEY PLAYERS
- GlaxoSmithKline plc
- Novartis AG
- Pfizer Inc.
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Roche Holding AG
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Sanofi S.A.
- Sunovion Pharmaceuticals Inc.
- Mylan N.V.
- Cipla Ltd.
- Grifols S.A.
- Insmed Incorporated
- Arbor Pharmaceuticals LLC
GLOBAL BRONCHIECTASIS DRUGS MARKET, BY DRUG CLASS
- Antibiotics
- Mucolytics
- Bronchodilators
- Anti-inflammatory agents
GLOBAL BRONCHIECTASIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
- Oral
- Inhalation
- Intravenous
GLOBAL BRONCHIECTASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL BRONCHIECTASIS DRUGS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
Rest of MEA
TABLE OF CONTENT
1. Bronchiectasis Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Bronchiectasis Drugs Market Snippet by Drug Class
2.1.2. Bronchiectasis Drugs Market Snippet by Route of Administration
2.1.3. Bronchiectasis Drugs Market Snippet by Distribution Channel
2.1.4. Bronchiectasis Drugs Market Snippet by Country
2.1.5. Bronchiectasis Drugs Market Snippet by Region
2.2. Competitive Insights
3. Bronchiectasis Drugs Key Market Trends
3.1. Bronchiectasis Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Bronchiectasis Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Bronchiectasis Drugs Market Opportunities
3.4. Bronchiectasis Drugs Market Future Trends
4. Bronchiectasis Drugs Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Bronchiectasis Drugs Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Bronchiectasis Drugs Market Landscape
6.1. Bronchiectasis Drugs Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Bronchiectasis Drugs Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
7.1.2. Antibiotics
7.1.3. Mucolytics
7.1.4. Bronchodilators
7.1.5. Anti-inflammatory agents
8. Bronchiectasis Drugs Market – By Route of Administration
8.1. Overview
8.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
8.1.2. Oral
8.1.3. Inhalation
8.1.4. Intravenous
9. Bronchiectasis Drugs Market – By Distribution Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
9.1.2. Hospital Pharmacies
9.1.3. Retail Pharmacies
9.1.4. Online Pharmacies
10. Bronchiectasis Drugs Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
10.2. North America
10.2.1. Overview
10.2.2. Bronchiectasis Drugs Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.2.5. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Bronchiectasis Drugs Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Bronchiectasis Drugs Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Bronchiectasis Drugs Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Bronchiectasis Drugs Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
11. Key Vendor Analysis- Bronchiectasis Drugs Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. GlaxoSmithKline plc
11.2.2. Novartis AG
11.2.3. Pfizer Inc.
11.2.4. AstraZeneca plc
11.2.5. Boehringer Ingelheim International GmbH
11.2.6. Roche Holding AG
11.2.7. Teva Pharmaceutical Industries Ltd.
11.2.8. Bayer AG
11.2.9. Sanofi S.A.
11.2.10. Sunovion Pharmaceuticals Inc.
11.2.11. Mylan N.V.
11.2.12. Cipla Ltd.
11.2.13. Grifols S.A.
11.2.14. Insmed Incorporated
11.2.15. Arbor Pharmaceuticals LLC
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
